Page last updated: 2024-09-05

lapatinib and Innate Inflammatory Response

lapatinib has been researched along with Innate Inflammatory Response in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (33.33)	29.6817
2010's	5 (41.67)	24.3611
2020's	3 (25.00)	2.80

Authors

Authors	Studies
Alem, F; Bhalla, N; Boghdeh, NA; Brown, JA; Chiem, K; Chiu, W; Cohen, CA; Das, S; De Jonghe, S; Durán, V; Dye, JM; Einav, S; Ghita, L; Ghosh, P; Huang, PT; Huie, KE; Jin, J; Jochmans, D; Karim, M; Khalil, AM; Kumar, S; Leyssen, P; Lo, CW; Martinez-Sobrido, L; Narayanan, A; Neyts, J; Pinsky, BA; Saul, S; Sibai, M; Solow-Cordero, DE; Tindle, C; Tran, DH; Wikswo, JP; Ye, C	1
Ding, K; Loftin, C; Yuan, Y; Zhan, CG; Zheng, F; Zhou, S; Zhou, Z	1
Zhan, CG; Zheng, F; Zhou, S	1
Balko, JM; Cook, RS; Elion, DL; Gonzales-Ericsson, PI; Hicks, DJ; James, JL; Koblish, HK; Nixon, MJ; Rahman, B; Sanchez, V; Scherle, PA; Werfel, TA	1
Brown, C; De Souza, P; Fox, P; Gebski, V; Hudson, M; Lee, CK; Lord, S	1
Feddersen, CR; Fletcher, EV; Goel, A; Koch, AT; Love-Homan, L; Simons, AL; Sobhakumari, A	1
Cameron, DA; Hall, PS; Hanby, A	1
Cristofanilli, M	1
Boussen, H; Cristofanilli, M; DeSilvio, M; Salazar, V; Spector, N; Zaks, T	1
Tuma, RS	1
Ben Ahmed, S; Blackwell, K; Boussen, H; Citrin, DL; DeSilvio, ML; Harris, J; Johnston, S; Kaufman, B; Lombardi, DP; LoRusso, P; Salazar, V; Spector, NL; Trudeau, M; Westlund, RE; Zaks, TZ	1

Reviews

1 review(s) available for lapatinib and Innate Inflammatory Response

Article	Year
Clinical data mining reveals analgesic effects of lapatinib in cancer patients. Scientific reports, 2021, 02-11, Volume: 11, Issue:1 Topics: Analgesics; Anti-Inflammatory Agents; Data Mining; Drug Repositioning; Humans; Inflammation; Lapatinib; Neoplasms; Prostaglandin-E Synthases	2021

Trials

3 trial(s) available for lapatinib and Innate Inflammatory Response

Article	Year
Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. British journal of cancer, 2013, Jul-09, Volume: 109, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Inflammation; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Leukocyte Count; Male; Megestrol Acetate; Middle Aged; Platelet Count; Prognosis; Quinazolines; Serum Albumin; Tamoxifen; Young Adult	2013
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Inflammation; Lapatinib; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines	2010
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Female; Humans; Immunoenzyme Techniques; Inflammation; Lapatinib; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Sensitivity and Specificity; Skin Neoplasms	2008

Other Studies

8 other study(ies) available for lapatinib and Innate Inflammatory Response

Article	Year
Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects. The Journal of clinical investigation, 2023, 10-02, Volume: 133, Issue:19 Topics: Animals; Antiviral Agents; COVID-19; Cytokines; Hepatitis C, Chronic; Humans; Inflammation; Lapatinib; Mice; SARS-CoV-2	2023
DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1. Scientific reports, 2020, 06-23, Volume: 10, Issue:1 Topics: Anti-Inflammatory Agents; Betacoronavirus; Computational Chemistry; Coronavirus Infections; COVID-19; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Repositioning; Humans; Inflammation; Lapatinib; Molecular Dynamics Simulation; Pandemics; Pneumonia, Viral; Prostaglandin-E Synthases; SARS-CoV-2	2020
Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1. Cancer research, 2019, 01-01, Volume: 79, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; c-Mer Tyrosine Kinase; Female; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflammation; Lapatinib; Lung Neoplasms; Macrophages; Mammary Neoplasms, Experimental; Mice; Necrosis; Phagocytosis; Receptor, ErbB-2; T-Lymphocytes, Regulatory; Tumor Microenvironment	2019
EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC. Molecular cancer research : MCR, 2013, Volume: 11, Issue:12 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Cytokines; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Inflammation; Lapatinib; NADPH Oxidase 4; NADPH Oxidases; Oligonucleotide Array Sequence Analysis; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Time Factors	2013
Lapatinib for inflammatory breast cancer. The Lancet. Oncology, 2009, Volume: 10, Issue:6 Topics: Antineoplastic Agents; Breast Neoplasms; Female; Genes, erbB-2; Humans; Inflammation; Lapatinib; Quinazolines	2009
Novel targeted therapies in inflammatory breast cancer. Cancer, 2010, Jun-01, Volume: 116, Issue:11 Suppl Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Delivery Systems; Fluorouracil; Humans; Inflammation; Lapatinib; Protein Kinase Inhibitors; Quinazolines	2010
Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials. Journal of the National Cancer Institute, 2007, Mar-07, Volume: 99, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Research Design; Trastuzumab; United States	2007
Lapatinib shows promise for inflammatory breast cancer. Cancer biology & therapy, 2007, Volume: 6, Issue:1 Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase II as Topic; Female; Humans; Inflammation; Lapatinib; Multicenter Studies as Topic; Quinazolines	2007